described CRS in around half of the patients receiving subcutaneous (but not intravenous) IL-15, who also had high IL-6 levels, suggesting that IL-15 stores could trigger proinflammatory cytokines release by myeloid cells (81). The gene discussed is IL15; the disease is congenital rubella syndrome.